Pfizer's vaccine for Clostridium difficile (C. diff) looks like it may join a growing list of candidates that have been shelved or delayed, after the shot failed to meet its primary objective in a ...

Video content above is prompted by the following: What are the main unmet needs for recurrent C difficile infections and how do you see the field evolving in the future?

How does recurrent C difficile infection impact health care resources utilization and other medical costs? What are the ways in which recurrent C difficile infection can adversely impact a patient ...

No reason was provided for the discontinuation. Zinplava ™ (bezlotoxumab) injection will be discontinued as of January 31, 2025, according to the Food and Drug Administration’s (FDA) drug ...

“Since introducing REBYOTA, Ferring has remained committed to making this therapy accessible and available to patients with recurrent C. diff infection (rCDI), regardless of where they receive care,” ...

This indicator covers the incidence of healthcare associated infections from Clostridium difficile (C. diff). It measures outcomes that reflect the quality of care or processes linked by evidence to ...

LPOXY’s plan is to take Sidiprev into a phase 2 study in hospitalized patients with Clostridioides difficile infection. Known as one of the superbugs that resists most antibiotics, C.

An international study of cancer patients with Clostridioides difficile infection (CDI) found recurrence rates were significant and ... would safely reduce antibiotic duration compared with usual care ...

Findings from a study by researchers from the University of Iowa highlights the potential role of the home environment in Clostridioides difficile transmission. Using data from a commercial insurance ...